A screening tool to detect interstitial lung disease in systemic sclerosis: the ILD-RISC score
Authors:
- Cosimo BruniCosimo Bruni
- Lorenzo TofaniLorenzo Tofani
- Håvard FretheimHFHåvard Fretheim
- Arthiha VelauthapillaiArthiha Velauthapillai
- Hilde BjørkekjærHBHilde Bjørkekjær
- Ilaria GalettiIGIlaria Galetti
- Alexandru GaraimanAGAlexandru Garaiman
- Mike O BeckerMike O Becker
- Anna-Maria Hoffmann-VoldAnna-Maria Hoffmann-Vold
- Jeska de Vries-BouwstraJeska de Vries-Bouwstra
Open Access
- 14 August 2025
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (12) , 6285-6293
Abstract
Objectives: As a screening tool for the presence of systemic sclerosis-associated interstitial lung disease (SSc-ILD) on high-resolution computed tomography (HRCT) is missing, we aimed to develop the ILD-RISC score, a risk algorithm to guide physicians in ordering HRCTs, with specific focus on follow-up visits. Methods: The nominal group technique was used to select items for the multivariable logistic regression with backward selection. The ILD-RISC score was developed from baseline visits of the derivation cohort. After identifying a cut-off favoring sensitivity >85% from the ROC curve, it was validated in a separate cross-sectional cohort, and then applied longitudinally in a specific SSc cohort with negative baseline HRCT. Results: In the derivation cohort (533 patients), 13 variables associated with the presence of SSc-ILD on HRCT were tested. The ILD-RISC score, including FVC%, DLCO/SB%, digital ulcers ever, age and SSc autoantibodies, showed an area under the curve of 79.1% (75.3–83.0%) for the presence of SSc-ILD on HRCT. An ILD-RISC score ≥0.3 had sensitivity 85.6% and specificity 53.6%, as confirmed in the validation cohort (247 patients). Among 819 patients with negative baseline HRCT, 170 developed SSc-ILD: a low ILD-RISC score was detected in almost 50% of the follow-up visits, supporting the sparing of HRCTs. Conclusion: The ILD-RISC score was developed and validated to predict the presence of SSc-ILD. Thus, the ILD-RISC score may help to decide when to order HRCTs at follow-up, allowing the reduction of costs and radiation exposure, but also at the time of SSc diagnosis when resources are limited.Keywords
Funding Information
- Gruppo Italiano Lotta alla Sclerodermia
- Novartis Foundation for Medical-biological Research
- Boehringer Ingelheim
- AstraZeneca
- Scleroderma Research Foundation (US8247389, EP2331143)
This publication has 30 references indexed in Scilit:
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic DiseasesArthritis & Rheumatology, 2024
- Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic SclerosisChest, 2021
- The multifaceted problem of pulmonary arterial hypertension in systemic sclerosisThe Lancet Rheumatology, 2021
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Respiratory Medicine, 2020
- Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic SclerosisArthritis & Rheumatology, 2020
- The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statementsThe Lancet Rheumatology, 2020
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseNew England Journal of Medicine, 2019
- Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic SclerosisArthritis & Rheumatology, 2019
- Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) databaseScandinavian Journal of Rheumatology, 2018
- Brief Report: Pulmonary Function Tests: High Rate of False‐Negative Results in the Early Detection and Screening of Scleroderma‐Related Interstitial Lung DiseaseArthritis & Rheumatology, 2015